These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1170 related articles for article (PubMed ID: 24678955)

  • 1. Darapladib for preventing ischemic events in stable coronary heart disease.
    ; White HD; Held C; Stewart R; Tarka E; Brown R; Davies RY; Budaj A; Harrington RA; Steg PG; Ardissino D; Armstrong PW; Avezum A; Aylward PE; Bryce A; Chen H; Chen MF; Corbalan R; Dalby AJ; Danchin N; De Winter RJ; Denchev S; Diaz R; Elisaf M; Flather MD; Goudev AR; Granger CB; Grinfeld L; Hochman JS; Husted S; Kim HS; Koenig W; Linhart A; Lonn E; López-Sendón J; Manolis AJ; Mohler ER; Nicolau JC; Pais P; Parkhomenko A; Pedersen TR; Pella D; Ramos-Corrales MA; Ruda M; Sereg M; Siddique S; Sinnaeve P; Smith P; Sritara P; Swart HP; Sy RG; Teramoto T; Tse HF; Watson D; Weaver WD; Weiss R; Viigimaa M; Vinereanu D; Zhu J; Cannon CP; Wallentin L
    N Engl J Med; 2014 May; 370(18):1702-11. PubMed ID: 24678955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial.
    O'Donoghue ML; Braunwald E; White HD; Lukas MA; Tarka E; Steg PG; Hochman JS; Bode C; Maggioni AP; Im K; Shannon JB; Davies RY; Murphy SA; Crugnale SE; Wiviott SD; Bonaca MP; Watson DF; Weaver WD; Serruys PW; Cannon CP; ; Steen DL
    JAMA; 2014 Sep; 312(10):1006-15. PubMed ID: 25173516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease.
    White H; Held C; Stewart R; Watson D; Harrington R; Budaj A; Steg PG; Cannon CP; Krug-Gourley S; Wittes J; Trivedi T; Tarka E; Wallentin L
    Am Heart J; 2010 Oct; 160(4):655-61. PubMed ID: 20934559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease.
    Wallentin L; Held C; Armstrong PW; Cannon CP; Davies RY; Granger CB; Hagström E; Harrington RA; Hochman JS; Koenig W; Krug-Gourley S; Mohler ER; Siegbahn A; Tarka E; Steg PG; Stewart RA; Weiss R; Östlund O; White HD;
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27329448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
    Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A;
    J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic inhibition of lipoprotein-associated phospholipase A
    Prasad M; Lennon R; Barsness GW; Prasad A; Gulati R; Lerman LO; Lerman A
    Int J Cardiol; 2018 Feb; 253():7-13. PubMed ID: 29306475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome.
    O'Donoghue ML; Braunwald E; White HD; Serruys P; Steg PG; Hochman J; Maggioni AP; Bode C; Weaver D; Johnson JL; Cicconetti G; Lukas MA; Tarka E; Cannon CP
    Am Heart J; 2011 Oct; 162(4):613-619.e1. PubMed ID: 21982651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Darapladib, a lipoprotein-associated phospholipase A2 inhibitor, in diabetic macular edema: a 3-month placebo-controlled study.
    Staurenghi G; Ye L; Magee MH; Danis RP; Wurzelmann J; Adamson P; McLaughlin MM;
    Ophthalmology; 2015 May; 122(5):990-6. PubMed ID: 25749297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial.
    Held C; White HD; Stewart RAH; Davies R; Sampson S; Chiswell K; Silverstein A; Lopes RD; Heldestad U; Budaj A; Mahaffey KW; Wallentin L;
    Am Heart J; 2019 Feb; 208():65-73. PubMed ID: 30572273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque.
    Serruys PW; García-García HM; Buszman P; Erne P; Verheye S; Aschermann M; Duckers H; Bleie O; Dudek D; Bøtker HE; von Birgelen C; D'Amico D; Hutchinson T; Zambanini A; Mastik F; van Es GA; van der Steen AF; Vince DG; Ganz P; Hamm CW; Wijns W; Zalewski A;
    Circulation; 2008 Sep; 118(11):1172-82. PubMed ID: 18765397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Self-Reported Health and Outcomes in Patients With Stable Coronary Heart Disease.
    Stewart RAH; Hagström E; Held C; Wang TKM; Armstrong PW; Aylward PE; Cannon CP; Koenig W; López-Sendón JL; Mohler ER; Hadziosmanovic N; Krug-Gourley S; Ramos Corrales MA; Siddique S; Steg PG; White HD; Wallentin L;
    J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial.
    Held C; White HD; Stewart RAH; Budaj A; Cannon CP; Hochman JS; Koenig W; Siegbahn A; Steg PG; Soffer J; Weaver WD; Östlund O; Wallentin L;
    J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29066452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.
    De Bruyne B; Pijls NH; Kalesan B; Barbato E; Tonino PA; Piroth Z; Jagic N; Möbius-Winkler S; Rioufol G; Witt N; Kala P; MacCarthy P; Engström T; Oldroyd KG; Mavromatis K; Manoharan G; Verlee P; Frobert O; Curzen N; Johnson JB; Jüni P; Fearon WF;
    N Engl J Med; 2012 Sep; 367(11):991-1001. PubMed ID: 22924638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.
    Holman RR; Coleman RL; Chan JCN; Chiasson JL; Feng H; Ge J; Gerstein HC; Gray R; Huo Y; Lang Z; McMurray JJ; Rydén L; Schröder S; Sun Y; Theodorakis MJ; Tendera M; Tucker L; Tuomilehto J; Wei Y; Yang W; Wang D; Hu D; Pan C;
    Lancet Diabetes Endocrinol; 2017 Nov; 5(11):877-886. PubMed ID: 28917545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50.
    Bonaca MP; Scirica BM; Creager MA; Olin J; Bounameaux H; Dellborg M; Lamp JM; Murphy SA; Braunwald E; Morrow DA
    Circulation; 2013 Apr; 127(14):1522-9, 1529e1-6. PubMed ID: 23501976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Darapladib, a reversible lipoprotein-associated phospholipase A2 inhibitor, for the oral treatment of atherosclerosis and coronary artery disease.
    Riley RF; Corson MA
    IDrugs; 2009 Oct; 12(10):648-55. PubMed ID: 19790016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: Five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial.
    Ensrud K; LaCroix A; Thompson JR; Thompson DD; Eastell R; Reid DM; Vukicevic S; Cauley J; Barrett-Connor E; Armstrong R; Welty F; Cummings S
    Circulation; 2010 Oct; 122(17):1716-24. PubMed ID: 20937977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity in Japanese dyslipidemic patients, with exploratory analysis of a PLA2G7 gene polymorphism of Val279Phe.
    Daida H; Iwase T; Yagi S; Ando H; Nakajima H
    Circ J; 2013; 77(6):1518-25. PubMed ID: 23439604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.
    Tricoci P; Huang Z; Held C; Moliterno DJ; Armstrong PW; Van de Werf F; White HD; Aylward PE; Wallentin L; Chen E; Lokhnygina Y; Pei J; Leonardi S; Rorick TL; Kilian AM; Jennings LH; Ambrosio G; Bode C; Cequier A; Cornel JH; Diaz R; Erkan A; Huber K; Hudson MP; Jiang L; Jukema JW; Lewis BS; Lincoff AM; Montalescot G; Nicolau JC; Ogawa H; Pfisterer M; Prieto JC; Ruzyllo W; Sinnaeve PR; Storey RF; Valgimigli M; Whellan DJ; Widimsky P; Strony J; Harrington RA; Mahaffey KW;
    N Engl J Med; 2012 Jan; 366(1):20-33. PubMed ID: 22077816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fractional flow reserve-guided PCI for stable coronary artery disease.
    De Bruyne B; Fearon WF; Pijls NH; Barbato E; Tonino P; Piroth Z; Jagic N; Mobius-Winckler S; Rioufol G; Witt N; Kala P; MacCarthy P; Engström T; Oldroyd K; Mavromatis K; Manoharan G; Verlee P; Frobert O; Curzen N; Johnson JB; Limacher A; Nüesch E; Jüni P;
    N Engl J Med; 2014 Sep; 371(13):1208-17. PubMed ID: 25176289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.